© 2026 Stocks Telegraph All rights reserved.
Most stock quote data provided by Financial Modeling Prep
Novavax, Inc. (NVAX) stock declined over -0.34%, trading at $8.90 on NASDAQ, down from the previous close of $8.93. The stock opened at $8.71, fluctuating between $8.64 and $8.96 in the recent session.
| Filing Date | Accepted Date | |
|---|---|---|
| Filing Date | Accepted Date | |
|---|---|---|
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| May 19, 2026 | 8.76 | 8.96 | 8.64 | 8.90 | 2.98M |
| May 18, 2026 | 9.22 | 9.33 | 8.71 | 8.93 | 4.82M |
| May 15, 2026 | 9.13 | 9.32 | 8.93 | 9.06 | 4.04M |
| May 14, 2026 | 9.15 | 9.37 | 8.86 | 9.35 | 4.6M |
| May 13, 2026 | 9.43 | 9.51 | 9.16 | 9.23 | 5.14M |
| May 12, 2026 | 9.23 | 9.93 | 9.20 | 9.62 | 6.13M |
| May 11, 2026 | 10.56 | 10.74 | 9.30 | 9.50 | 10.28M |
| May 08, 2026 | 9.36 | 10.75 | 9.32 | 10.11 | 13.28M |
| May 07, 2026 | 9.67 | 10.20 | 9.16 | 9.23 | 9.11M |
| May 06, 2026 | 8.56 | 9.57 | 8.35 | 9.36 | 16.15M |
| May 05, 2026 | 8.10 | 8.16 | 7.81 | 8.10 | 3.5M |
| May 04, 2026 | 8.03 | 8.36 | 7.96 | 8.03 | 3.41M |
| Apr 30, 2026 | 8.01 | 8.27 | 7.92 | 7.93 | 2.8M |
| Apr 29, 2026 | 7.83 | 7.99 | 7.71 | 7.97 | 2.82M |
| Apr 28, 2026 | 8.08 | 8.10 | 7.87 | 7.92 | 3.28M |
| Apr 27, 2026 | 8.17 | 8.33 | 7.97 | 8.07 | 2.64M |
| Apr 23, 2026 | 8.43 | 8.50 | 7.98 | 8.15 | 3.57M |
| Apr 22, 2026 | 8.54 | 8.65 | 8.40 | 8.45 | 3.52M |
| Apr 21, 2026 | 8.67 | 8.74 | 8.41 | 8.49 | 3.95M |
| Apr 20, 2026 | 8.73 | 8.85 | 8.60 | 8.67 | 2.75M |
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
| Employees | 952 |
| Beta | 2.63 |
| Sales or Revenue | $983.71M |
| 5Y Sales Change% | 1.977% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |